The Initial Public Offering (IPO) landscape for the HealthTech and MedTech sectors is projected to undergo a significant recovery in 2026. Following a period of volatility and retrenchment between 2022 and 2024, the confluence of stabilising macroeconomic conditions, investor appetite for disruptive technology and a substantial backlog of highly mature companies suggests that 2026 will be the most active year for public offerings since the market peaks of 2021.